Trials / Terminated
TerminatedNCT03533946
Rucaparib in Nonmetastatic prOstAte With BRCAness
A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- University of Utah · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single arm, open label, phase II trial to assess efficacy of rucaparib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rucaparib | Treatment with rucaparib will begin on Cycle 1 Day 1 and continue at 600 mg twice daily. Therapy continues until Prostate Specific Antigen (PSA) progression or intolerable toxicities. |
Timeline
- Start date
- 2019-05-20
- Primary completion
- 2023-01-12
- Completion
- 2023-01-12
- First posted
- 2018-05-23
- Last updated
- 2024-03-13
- Results posted
- 2024-03-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03533946. Inclusion in this directory is not an endorsement.